ДИСФУНКЦИЯ ЖИРОВОЙ ТКАНИ ПРИ ПОЛИЭНДОКРИННО-МЕТАБОЛИЧЕСКОМ ОВАРИАЛЬНОМ СИНДРОМЕ: АДИПОКИНЫ, ГЕПАТОКИНЫ И МЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯ
- Authors
-
-
Пирмухамедова Гулноза Нигматовна
Частная клиника «Nora Medical», Ташкент, Узбекистан
Author
-
Тожиева Ирода Мирсоли кизи
Ташкентский Государственный Медицинский Университет, Ташкент, Узбекистан
Author
-
- Keywords:
- Array
- Abstract
-
Полиэндокринно-метаболический овариальный синдром (ПМОС), ранее обозначавшийся как синдром поликистозных яичников (СПКЯ), сочетает репродуктивные и метаболические нарушения. Все больше данных указывает, что метаболический риск определяется не только количеством жировой ткани, но и ее функциональным состоянием. При ПМОС описаны гипертрофия адипоцитов, нарушение адипогенеза, снижение чувствительности к инсулину, изменения липолиза и секреторной активности, в том числе у женщин с нормальным ИМТ. Наиболее изученными адипокинами остаются адипонектин, лептин, резистин и хемерин. Одновременно возрастает интерес к печени как активному участнику метаболических нарушений и к гепатокинам — фетуину-А, FGF-21, селенопротеину P и ANGPTL3. В обзоре рассмотрены основные механизмы взаимосвязи гиперандрогении, инсулинорезистентности, жировой ткани и печени, а также их возможное клиническое значение.
- References
-
Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158(7):1899–1912.
Behboudi-Gandevani S, Amiri M, Yarandi RB, et al. The risk of metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;88(2):169–184.
Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study. J Clin Endocrinol Metab. 2021;106(9):e3369–e3380.
Blouin K, Nadeau M, Perreault M, et al. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf). 2010;72(2):176–188.
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855.
Bril F, Ezeh U, Amiri M, et al. Adipose tissue dysfunction in polycystic ovary syndrome. J Clin Endocrinol Metab. 2024;109(1):10–24.
Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631.
Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78(9):920–926.
Chazenbalk G, Trivax BS, Yildiz BO, et al. Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-α. J Clin Endocrinol Metab. 2010;95(2):935–942.
Chen YH, Heneidi S, Lee JM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 2013;62(7):2278–2286.
Dumesic DA, Akopians AL, Madrigal VK, et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101(11):4178–4188.
Dumesic DA, Phan JD, Leung KL, et al. Adipose insulin resistance in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(6):2171–2183.
Ezeh U, Chen IY, Chen YH, Azziz R. Adipocyte insulin resistance in PCOS: relationship with GLUT-4 expression and whole-body glucose disposal and β-cell function. J Clin Endocrinol Metab. 2020;105(7):e2408–e2420.
Ezeh U, Arzumanyan Z, Lizneva D, et al. Alterations in plasma non-esterified fatty acid kinetics and relationship with insulin resistance in polycystic ovary syndrome. Hum Reprod. 2019;34(2):335–344.
Freitas de Medeiros S, Maciel GAR. Relationship between adipose tissue and liver dysfunction in women with polycystic ovary syndrome and metabolic syndrome. Metabolites. 2026;16:393.
Iglesias P. The endocrine role of hepatokines: implications for human health and disease. Front Endocrinol. 2025;16:1663353.
Lin K, Sun X, Wang X, Wang H, Chen X. Circulating adipokine levels in nonobese women with polycystic ovary syndrome and in nonobese control women: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:537809.
Mannerås-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96(2):E304–E311.
Miao X, Alidadipour A, Saed V, et al. Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation. Acta Diabetol. 2024;61:1339–1361.
Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One. 2017;12(11):e0186136.
Schüler-Toprak S, Ortmann O, Buechler C, Treeck O. The complex roles of adipokines in polycystic ovary syndrome and endometriosis. Biomedicines. 2022;10(10):2503.
Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407:1–10.
Zhang Y, Wang Y, Liu J. Friend or foe for obesity: how hepatokines remodel adipose tissues and translational perspective. Genes Dis. 2023;10:825–847.
- Downloads
- Published
- 2026-10-09
- Section
- Articles